Document Actions

You are here: Home Faculty Professors Meyer

Meyer

Prof. Dr. Dr.
Philipp T. Meyer

Department of Nuclear Medicine
Medical Director
Phone: 0049-761-270-39160

www.uniklinik-freiburg.de/nuklearmedizin

CV

  • 1994-2000 RWTH Aachen University & University of Pennsylvania, medical studies (degree 2000), medical doctorate (2001)
  • 2002-2005 Research Center Jülich, Institute of Medicine, postdoc
  • 2004-2007 University of Cologne, Interdisciplinary Program Molecular Medicine (doctorate 2007)
  • 2001-2002 / 2005-2008 University Hospitals Aachen and Leipzig, resident, Nuclear Medicine and Neurology, Nuclear Medicine board certification (2008)
  • Since 2008 Full Professor (W3) and Medical Director, Department of Nuclear Medicine, Medical Center - University of Freiburg

Focus of research

  • Molecular neuroimaging with PET und SPECT, focus on diagnosis and prognosis of neurodegenerative diseases
  • Preclinical and clinical development and evaluation of radiopharmaceuticals for neurological and oncological imaging and therapy (emphesis on receptor ligands)
  • Methods development (PET/CT and SPECT/CT, tracerkinetic quantification)

Selected publications

  • Jilg CA, … Meyer PT. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer. Theranostics. 2017; 7:1770-80.
  • Stoykow C, ... Meyer PT. Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist 68Ga-RM2 And PET. Theranostics. 2016; 6:1641-50.
  • Frings L, ... Meyer PT. Asymmetries of amyloid-β burden and neuronal dysfunction are positively correlated in Alzheimer's disease. Brain. 2015; 138:3089-99.
  • Hellwig S, ... Meyer PT. [¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology. 2012; 79:1314-22.
  • Meyer PT et al. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. J Nucl Med. 2011; 52:393-400.

Research methods

  • Hybrid imaging (PET/CT and SPECT/CT)
  • Preclinical imaging (small animal PET and CT)
  • Radiopharmacy (cyclotron, GMP production)